Şunu aradınız:: neoplastic (İngilizce - Maltaca)

neoplastic proliferation
proliferazzjoni neoplastika

neoplastic histopathological findings,
sejbiet istopatoloġiċi neoplastiċi,

non neoplastic histopathological findings,
sejbiet istopatoloġiċi mhux neoplastiċi,

anti-neoplastic, immunomodulatory or immunosuppressive therapies
terapiji b’antineoplastiċi, immunomodulatorji jew b’immunosuppressivi

combination with other anti-neoplastic agents:
kombinazzjoni ma ’ aġenti oħra anti- neoplastiċi:

pcr (absence ofinvasive neoplastic cells in breast
pcr (nuqqas ta’ ċelluli neoplastiċi invażivi fis-sider)

regarding susceptibility to infection and neoplastic conditions, see section 4.5.
ara sezzjoni 4.5 dwar suxxettibilità għall-infezzjoni u kundizzjonijiet neoplastiċi.

this study did not control for prognostic factors and anti-neoplastic treatments.
dan l-istudju ma kellux kontroll għall-ksur pronjostiku u għal trattament anti- neoplastiku.

absence of relevant pathogenicity or neoplastic changes in a suitable long term inhalation test.
in-nuqqas ta’ patoġenoċità rilevanti jew bidliet neoplastiċi f’test fit-tul xieraq ta’ inalazzjoni.

oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions.
oclacitinib jimmodula s-sistema immunitarja u jista’ jżid is-suxxettibbiltà għall-infezzjoni u jiggrava kundizzjonijiet neoplastiċi.

in two 9 month studies in monkeys there were no pre-neoplastic or neoplastic tissue observed.
f’żewġ studji li damu 9 xhur fuq ix-xadini, ma ġie osservat l-ebda tessut preneoplastiku jew neoplastiku.

the observed neoplastic changes are well known hormonal and centrally mediated effects in the rat which are not relevant for humans.
il-bidliet neoplastiċi osservati huma effetti ormonali u medjati ċentralment magħrufa sew fil-far li mhumiex rilevanti għall- bnedmin.

capecitabine accord should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic medicinal products.
capecitabine accord għandu jiġi preskritt biss minn tobba kkwalifikati b’esperjenza fl-użu ta’ prodotti mediċinali anti-neoplastiċi.

in a study to assess potential carcinogenicity in transgenic rash2 mice, no treatment related increases in the incidence of neoplastic lesions were observed.
fi studju biex jevalwa l-karċinoġeniċità potenzjali fi ġrieden transġeniċi rash2, ma kienu osservati l-ebda żiediet relatati mal-kura fl-inċidenza ta’ leżjonijiet neoplastiċi.

non-neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth.
leżjonijiet mhux neoplastiċi li ma kienux identifikati fi studji ta’ qabel l-użu kliniku kienu s-sistema kardjovaskolari, il-pankreas, l-organi endokrini u s-snien.

anti-neoplastic, immunomodulatory or immunosuppressive therapies should not be co-administered due to the risk of additive immune system effects.
terapiji anti-neoplastiċi, immunomodulatorji jew immunosoppressivi m’għandhomx jingħataw flimkien minħabba r-riskju ta’ effetti addittivi fuq is-sistema immuni.

tecfidera has not been studied in combination with anti-neoplastic or immunosuppressive therapies and caution should, therefore, be used during concomitant administration.
tecfidera ma ġiex studjat flimkien ma’ terapiji antineoplastiċi jew immunosoppressivi u għalhekk għandha tintuża kawtela matul l-għoti fl-istess ħin.

the lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties.
il-mekkaniżmu ta’ l-azzjoni ta’ lenalidomide jinkludi proprjetajiet anti-neoplastiċi, anti-anġjoġeniċi, pro-eritropojetiċi, u immunomodulatorji.

risk factors associated with interstitial lung disease include prior or concomitant therapy with other anti-neoplastic therapies known to be associated with it such as taxanes, gemcitabine, vinorelbine and radiation therapy.
fatturi ta’ riskju assoċjati ma’ mard tal-interstizu tal-pulmuni jinkludu terapija qabel jew fl-istess waqt b’terapiji anti-neoplastiċi oħra magħrufa li huma assoċjati ma dan bħal taxanes, gemcitabine, vinorelbine u terapija ta’ radjazzjoni.

culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders.
deni li huwa negattiv għall-koltura (‘culture-negative fever’) wara t-trattament bi cladribine iseħħ f’10-40% tal-pazjenti b’lewkimja taċ-ċelluli ċiljati u rarament kien osservat f’pazjenti b’mard neoplastiku ieħor.